Navigation Links
Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
Date:5/18/2009

ORLANDO, May 18 /PRNewswire-USNewswire/ -- A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

They say the agent, pregabalin, decreased hot flash severity and frequency about 20 percent more than did a placebo agent. Thus, pregabalin appears to offer about the same benefit as gabapentin, an older, related drug, as well as newer classes of antidepressants.

"Hot flashes are a major problem in many women, and for those who opt not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option," says the study's lead author, Charles Loprinzi, M.D., a medical oncologist at the Mayo Clinic in Minnesota.

While pregabalin offers about the same benefit as gabapentin, women who use it only need to take two pills a day, versus three for gabapentin, he says. Side effects can occur with the use of either drug. However, in this study, they were not severe enough that participants stopped using the active study drug any more often than did patients who were taking placebos, researchers say.

Dr. Loprinzi has pioneered the field of nonhormonal hot flash therapy, which he began researching decades ago to help breast cancer patients using tamoxifen, an anti-estrogen treatment that creates symptoms of menopause. He is the first researcher to test the use of antidepressants, compared to placebo treatment, for hot flashes.

Gabapentin, an agent that has long been on the market to treat pain caused from injury to nerves, has been shown to decrease hot flashes more than do placebos. This drug is approved by the Food and Drug Administration (FDA) to
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
2. Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
3. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
4. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
5. Large clinical trial finds pirfenidone may help lung function in IPF patients
6. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
7. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
8. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
9. Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz.
10. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
11. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
(Date:4/23/2014)... at the National Institute of Arthritis and Musculoskeletal and ... of the Ross Prize in Molecular Medicine, conferred by ... . The award will be given on June 9 ... followed by scientific presentations by Dr. O,Shea and other ... of Health. , The award, which includes a $50,000 ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... targets an important brain receptor has a dramatic effect ... behavior, a University at Buffalo animal study has found. ... be a novel lead compound for treating cocaine addiction, ... was published as an online preview article in ... compound, RO5263397, severely blunted a broad range of cocaine ...
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
Breaking Medicine News(10 mins):Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3
... received nearly $1 million from the U.S. Department of ... green healthy housing. , The funding was made available ... , UIC researchers will evaluate the health and monetary ... housing into green, affordable, healthy housing. , At a ...
... RN StaffingSILVER SPRING, Md., May 7 Leaders and members ... efforts to secure passage of landmark legislation --reintroduced last night ... RN staffing ratios the law of the land. "As ... better gift for RNs and their patients than the assurance ...
... /PRNewswire/ -- The AANS/CNS Section on Tumors ... BrainLAB Community Neurosurgery Award. Eric Nussbaum, MD, from Minneapolis, ... Results and Complications of the Middle Fossa Approach for ... presented with the award during the 2009 AANS Annual ...
... 7 PARI Pharma GmbH received an Orphan Drug ... positive recommendation by the EMEA for inhaled PARI Tobramycin ... This is the second ODD designation that PARI ... drug pipeline; the first ODD was granted for PARI,s ...
... 2009 In a letter to the Editor of the ... by Elsevier, S. Lefebvre and J.S. Weese from the University ... MRSA and C.difficile could be passed between pet ... C. difficile may have been transferred to the ...
... a considerable number of people worldwide. Although the introduction ... revolutionized treatment of peptic ulcers and other gastrointestinal disorders, ... It has been shown that long term use of ... Relapses of the malady, ineffectiveness of different drug regimens ...
Cached Medicine News:Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:UAN Hails Reintroduction of Federal RN Staffing Ratio Bill and Vows to Work for Passage 2Health News:AANS/CNS and BrainLAB Announce Winner of 2009 BrainLAB Community Neurosurgery Award 2Health News:AANS/CNS and BrainLAB Announce Winner of 2009 BrainLAB Community Neurosurgery Award 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4Health News:Transmission of MRSA and Clostridium difficile through dogs 2Health News:A potential anti-ulcer herb medicine: Rocket 'Eruca sativa' 2
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... WA – June 25 – MediQuest Therapeutics,Inc., ... for inflammatory and infectious diseases, today announced,the ... of Vascana,– a topical formulation designed to ... primary end point and demonstrated statistical,significance, with ...
... Company updates progress and upcoming,milestones on its ... /PRNewswire-FirstCall/ - SemBioSys,Genetics Inc. , a biotechnology ... metabolic and cardiovascular disease,today announced positive preclinical ... insulin. The Company,presented its findings at the ...
Cached Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
... the Attain Prevail's steerable tip, along with ... to obtain the curve you need, when ... improved visualization of the cardiac venous anatomy, ... Telescoping - Adjust curve and reach ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Hancock Standard Mitral bioprosthesis is ... predictable results based on 25 ... long-term performance makes it an ... mitral valve replacement--particularly elderly patients ...
Medicine Products: